TNFSF11 and osteoporosis: Based on the mechanism of the RANKL-RANK-OPG pathway, denosumab, an inhibitor of RANKL, was approved by the FDA for severe osteoporosis, SRES, and nonresectable or metastatic giant cell tumors of bone and got promising results [77, 78].